PA
SNBR

PharVision Advisers’s Sleep Number SNBR Stock Holding History

PharVision Advisers’s Portfolio SNBR Stock Details SNBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,914
Closed -$133K – 980
2025
Q3 		$133K Buy
+18,914
New +$166K 0.07% 589

Other funds holding SNBR

SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PRCP
Pacific Ridge Capital Partners Lake Oswego, Oregon $462M AUM 40.76% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

PharVision Advisers's SNBR Position: Q4 2025 in Review

PharVision Advisers sold out of Sleep Number (SNBR) in Q4 2025, closing a stake of 18,914 shares — an estimated $133K sold.

PharVision Advisers first reported a position in SNBR in Q3 2025 and held it in 1 quarter. The position peaked at $133K in Q3 2025. 127 funds tracked by Wall St. Rank hold SNBR as of Q4 2025.

  • PharVision Advisers reported no remaining Sleep Number position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 18,914 Sleep Number shares in Q4 2025, an estimated $133K.
  • PharVision Advisers first reported a position in Sleep Number in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Sleep Number position peaked at $133K in Q3 2025.
  • 127 funds tracked by Wall St. Rank held Sleep Number as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.